View in EDS

Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.

Saved in:
Bibliographic Details
Title: Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.
Authors: Pu X; Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China., Li J; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, 610000, China., Zhang B; Shanghai Chest Hospital, Jiao Tong University, Shanghai, 200025, China., Zhang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China., K Mok TS; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, 999077, China., Nakagawa K; Department of Medicine, Kindai University Hospital, Osaka, 589-8511, Japan., Rosell R; Dr. Rosell Oncology Institute & Quirón-Dexeus University Institute, Barcelona, 08028, Spain., Cheng Y; Jilin Provincial Cancer Hospital, Changchun, China., Zhou X; First Affiliated Hospital of Third Military Medical University, Chongqing, 400038, China., Miglorino MR; Pneumological Oncology, San Camillo Forlanini Hospital, Roma, 00152, Italy., Niho S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 2778577, Japan., Lee KH; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, 28644, South Korea., Corral J; Clínica Universidad de Navarra, Madrid, 28027, Spain., Pluzanski A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-034, Poland., Li J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China., Linke R; SFJ Pharmaceuticals Inc., Pleasanton, CA 94588, USA., Pan F; Pfizer, Beijing, 100010, China., Tang Y; Pfizer, San Diego, CA 92121, USA., Tan W; Pfizer, San Diego, CA 92121, USA., Wu L; Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Source: Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (37), pp. 2971-2982. Date of Electronic Publication: 2024 Oct 03.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39360943
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Pu+X%22">Pu X</searchLink>; Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, 610000, China.<br /><searchLink fieldCode="AU" term="%22Zhang+B%22">Zhang B</searchLink>; Shanghai Chest Hospital, Jiao Tong University, Shanghai, 200025, China.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China.<br /><searchLink fieldCode="AU" term="%22K+Mok+TS%22">K Mok TS</searchLink>; Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Hong Kong, 999077, China.<br /><searchLink fieldCode="AU" term="%22Nakagawa+K%22">Nakagawa K</searchLink>; Department of Medicine, Kindai University Hospital, Osaka, 589-8511, Japan.<br /><searchLink fieldCode="AU" term="%22Rosell+R%22">Rosell R</searchLink>; Dr. Rosell Oncology Institute & Quirón-Dexeus University Institute, Barcelona, 08028, Spain.<br /><searchLink fieldCode="AU" term="%22Cheng+Y%22">Cheng Y</searchLink>; Jilin Provincial Cancer Hospital, Changchun, China.<br /><searchLink fieldCode="AU" term="%22Zhou+X%22">Zhou X</searchLink>; First Affiliated Hospital of Third Military Medical University, Chongqing, 400038, China.<br /><searchLink fieldCode="AU" term="%22Miglorino+MR%22">Miglorino MR</searchLink>; Pneumological Oncology, San Camillo Forlanini Hospital, Roma, 00152, Italy.<br /><searchLink fieldCode="AU" term="%22Niho+S%22">Niho S</searchLink>; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 2778577, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+KH%22">Lee KH</searchLink>; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, 28644, South Korea.<br /><searchLink fieldCode="AU" term="%22Corral+J%22">Corral J</searchLink>; Clínica Universidad de Navarra, Madrid, 28027, Spain.<br /><searchLink fieldCode="AU" term="%22Pluzanski+A%22">Pluzanski A</searchLink>; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, 02-034, Poland.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100005, China.<br /><searchLink fieldCode="AU" term="%22Linke+R%22">Linke R</searchLink>; SFJ Pharmaceuticals Inc., Pleasanton, CA 94588, USA.<br /><searchLink fieldCode="AU" term="%22Pan+F%22">Pan F</searchLink>; Pfizer, Beijing, 100010, China.<br /><searchLink fieldCode="AU" term="%22Tang+Y%22">Tang Y</searchLink>; Pfizer, San Diego, CA 92121, USA.<br /><searchLink fieldCode="AU" term="%22Tan+W%22">Tan W</searchLink>; Pfizer, San Diego, CA 92121, USA.<br /><searchLink fieldCode="AU" term="%22Wu+L%22">Wu L</searchLink>; Second Department of Thoracic Oncology, Hunan Cancer Hospital/Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2024; Vol. 20 (37), pp. 2971-2982. <i>Date of Electronic Publication: </i>2024 Oct 03.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Multicenter Study; Clinical Trial, Phase III; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39360943
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2024.2404762
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2971
    Titles:
      – TitleFull: Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Pu X
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Zhang B
      – PersonEntity:
          Name:
            NameFull: Zhang J
      – PersonEntity:
          Name:
            NameFull: K Mok TS
      – PersonEntity:
          Name:
            NameFull: Nakagawa K
      – PersonEntity:
          Name:
            NameFull: Rosell R
      – PersonEntity:
          Name:
            NameFull: Cheng Y
      – PersonEntity:
          Name:
            NameFull: Zhou X
      – PersonEntity:
          Name:
            NameFull: Miglorino MR
      – PersonEntity:
          Name:
            NameFull: Niho S
      – PersonEntity:
          Name:
            NameFull: Lee KH
      – PersonEntity:
          Name:
            NameFull: Corral J
      – PersonEntity:
          Name:
            NameFull: Pluzanski A
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Linke R
      – PersonEntity:
          Name:
            NameFull: Pan F
      – PersonEntity:
          Name:
            NameFull: Tang Y
      – PersonEntity:
          Name:
            NameFull: Tan W
      – PersonEntity:
          Name:
            NameFull: Wu L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 37
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1